HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Thomas W. Rice Thomas J. Kirby Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rice, T. W. Articles by Bukowski, R. M. Search for Related Content PubMed PubMed Citation Articles by Rice, T. W. Articles by Bukowski, R. M.

Ann Thorac Surg 1995;59:568-572
© 1995 The Society of Thoracic Surgeons

Expression of Blood Group Antigen A by Stage I Non–Small Cell Lung Carcinomas

Departments of Thoracic and Cardiovascular Surgery, Clinical Pathology, Hematology and Medical Oncology, Pulmonary and Critical Care Medicine, and Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio

To clarify the significance of blood group antigen A (BAA) expression by neoplastic cells, we studied patients who had curative resections of stage I non–small cell lung carcinomas. Immunohistochemical staining using monoclonal antibodies was used to detect BAA expression by paraffin-embedded carcinoma cells. One hundred three patients were studied; mean age was 62.6 years, and 70 (68%) were male. Histologic types were as follows: adenocarcinoma, 52 (50.5%); squamous cell, 25 (24.3%); large cell, 24 (23.3%); and adenosquamous, 2 (1.9%). Histologic grades were as follows: I, 13 (12.6%); II, 26 (25.3%); and III, 64 (62.1%). All patients had American Joint Committee on Cancer stage I tumors: 65 patients (63.1%) had T1 tumors, and 38 (36.9%) had T2 tumors. Recurrences developed in 25 (24.3%) and metachronous malignancies in 4 (3.9%). Survival was 75% ± 4.8% at 3 years and 66.6% ± 7.5% at 5 years. Eighty-nine patients (86.4%) were blood group A and 14 (13.6%) were AB. Ninety-five (92.2%) were secretors of BAA and 8 (7.8%) were not. The expression of BAA by neoplastic cells was not detectable in 34 (33%), trace (1% to 5% of neoplastic cells) in 10 (9.7%), 1+ (6% to 25%) in 8 (7.8%), 2+ (26% to 50%) in 12 (11.7%), 3+ (51% to 75%) in 12 (11.7%), and 4+ (76% to 100%) in 27 (26.2%). The pattern of neoplastic cell staining was homogeneous in 14 patients (20.3%) and heterogenous in 55 (79.7%). Carcinoma recurrence, overall survival, and event-free survival were not related to secretor status, BAA expression, or pattern of staining. Based on recurrence and survival analyses we conclude that secretor status, expression of BAA, and pattern of staining were not of prognostic significance.

This article has been cited by other articles:

				J. C. Nesbitt, J. B. Putnam Jr, G. L. Walsh, J. A. Roth, and C. F. Mountain Survival in Early-Stage Non--Small Cell Lung Cancer Ann. Thorac. Surg., August 1, 1995; 60(2): 466 - 472. [Abstract] [Full Text]